摘要
糖尿病肾病(diabetic kidney disease,DKD)是糖尿病患者发生的慢性肾功能损伤,最终发展为肾功能衰竭.糖尿病肾病是全球慢性肾病(CKD)和终末期肾病(ESRD)的主要病因之一.肾小球损伤可能会引起大量尿蛋白流失,并导致血清白蛋白降低、患者全身肿胀(水肿)并导致肾病综合征.药物治疗主要通过抑制肾素-血管紧张素-醛固酮系统(RAAS),RAAS抑制已被证明是延缓糖尿病肾病各个阶段进展的最有效疗法.近年来随着新药物的不断研发,糖尿病肾病相关治疗药物有了长足的进步,患者的预后有了明显改善.此文对糖尿病肾脏疾病药物治疗相关研究文献进行了复习并予以综述.
Diabetes nephropathy(DKD)is a chronic renal function injury n ipatients with diabetes,which eventually develops into rena l failure.Diabetes nephropathy is one of the major causes of chnrioc kidney disease(CKD)and end-stage renal disease(ESRD)itnh e world.The loss of urinary protein caused by glomerular injury may boemce large and lead to the decrease of serum albumin,resultingn isystemic swelling(edema)and nephrotic syndrome.Drug therapy is mainlyt hrough inhibition of renin angiotensin aldosterone system(RASA).RAAS inhibition has been proved to be the most effective therya pto delay the progress of diabetes nephropathy at all stagesn.Irecent years,with the continuous research and development of new drug,sthe drugs related to diabetes nephropathy have made great prroegss,and the prognosis of patients has been significantly improved.Thisa rticle reviews and summarizes the related research literatureo n the drug treatment of diabetes kidney disease.
作者
张艳
Zhang Yan(Department of Endocrinology,Jinghai Clinical College,Tianjin Medical University(Tianjin Jinghai district hospital),Tianjin 301600,China)
出处
《首都食品与医药》
2022年第18期17-19,共3页
Capital Food Medicine
关键词
2型糖尿病
糖尿病肾病
药物
安全性
进展
预后
type 2 diabetes
diabetes nephropathy
drugs
safety
progress
prognosis
